1122 GMT - AstraZeneca's sales beat and key catalysts for 2025 outshine its core operating profit miss, Barclays analysts says in a note. The British pharma giant's oncology drugs beat sales expectations, driven by lung-cancer drug Tagrisso and breast-cancer treatment Lynparza, Barclays says. However, its core operating profit margin missed company-compiled consensus by 30%, they say. "We see AstraZeneca as having the strongest catalyst path in 2025 of any company in our coverage," the analysts say. Shares are up 5.1% at 116.92 pounds. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 06, 2025 06:22 ET (11:22 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。